Mainz Biomed Presents ColoAlert® Cancer Screening Innovation at 2024 UDH Congress

Molecular genetics diagnostics company, Mainz Biomed N.V. (Nasdaq: MYNZ) presented its ColoAlert® cancer screening innovation at the 39th UDH Congress in Fellbach, Germany this month. ColoAlert, the company’s flagship product, offers a highly accurate, easy-to-use, at-home colorectal cancer (CRC) screening kit with  advanced tumor DNA analysis technology, which significantly improves early detection rates, a crucial factor in effective CRC management.

Also this month, the company organized the HALLO DOC! event, which delivered education and information about colorectal cancer, cutting-edge research, new treatment modalities, and holistic therapeutic approaches. The event took place in Berlin, Germany, aligning with the Colorectal Cancer Awareness Month.

Mainz Biomed says its presentation and events highlight the important role of cutting-edge molecular diagnostics in enhancing comprehensive health strategies.

The company is at the forefront of developing market-ready, molecular-genetic diagnostic solutions for life-threatening conditions. 

About Mainz Biomed N.V.

Mainz Biomed develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The Company’s flagship product is ColoAlert®, an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. ColoAlert® is currently marketed across Europe. The Company is running a pivotal FDA clinical study for US regulatory approval. Mainz Biomed’s product candidate portfolio also includes PancAlert, an early-stage pancreatic cancer screening test. To learn more, visit

Share This Article


About the Author

Mainz Biomed Presents ColoAlert® Cancer Screening Innovation at 2024 UDH Congress

Catie Corcoran

Biotech Editor